x 0

Oh! is actually the Executive Chairman' s method so apology to the CEO but well done EC! Now I can evaluate all other O& G E& P coy within seconds. A real time saver!

edwinjup ( Date: 16-May-2014 18:24) Posted:

I think this ceo resign liao....

sheerluck ( Date: 16-May-2014 18:17) Posted:

for the CEO' s method of valuing his coy. Trumps all analysts out there.

x 0

for the CEO' s method of valuing his coy. Trumps all analysts out there.

lucky168 ( Date: 15-May-2014 20:58) Posted:

read this article at nextinsight on how RH Petrogas can probably be valued. Not to take it seriously, read with a pinch of salt

Taking 613 million issued shares (post-conversion of debt to equity for the Tiong family) and 148 million barrels of oil (unrisked contingent resources, see chart on the top right), the value of 1 share is equal to 0.24 of a barrel of oil.

Taking a barrel to be worth US$100, one RH Petrogas share is worth US$24.

From here, you can discount it by, say, 50% for the cost of production, and another 50% for risks (even though RH Petrogas emphasises low-to-medium risk ventures) and a further 50% for ' other factors' .

Result: US$3 (S$3.75).

x 0

Last year when NCL resutls its FY12 results its price when from 25cts to 30cts before end of May

End of last year when NCL annouced contract wins its price when from 29cts to 34cts within 10 days.

NCL is trading around 35.5cts with its Q1 release. Can I expect it to breach 40cts before end of May??? i think it is a fair expectation but lets see what the Market thinks?

DYDD.

x 0

Based on NCL this quarter earning and current price of 37.5cts, its trading at PE of 7.2x. For a company that has demonstrated a net profit with a CAGR of 14.5% for the past three years and and exceptional Q1 results, surely it deserves a higher PE. The average PE for this sector is 8-10. Better ones can and should command a higher PE.

I draw comparison to VARD which is now trading at a PE of 16. VARD is a good company with a strong order book trading at twice NCL' s PE. It is currently facing issues with one of its Brazilian yard but market participants still trade VARD in anticipation to a recovering story. To match NCL' s current PE, it need to more than doble its earning.

So is it better to trade with anticipation or with proven track record? You decide.

As mentioned in my earlier post, NCL doesn' t shoot to the sky like some other counters on good news but rather it does a series of mini re-rates. Slow yes but definitely steady but every re-rate lifted it s base higher. This I draw comparison to Penguin which reported a sterling Q1 results and it price shoot up more than 10% but look what is happening to it now.

This is my personal view of NCL in general.

Please DYDD.

x 0

Correction:

Drop in GM for MNG is a surprise. Reason being due to the change in business model. A pity because maintaining the usual 30+% GM would have given it a PE of 11X based on the price of 26.5/27cts. Now the PE is 15x.

DYDD.

sheerluck ( Date: 12-May-2014 10:46) Posted:

IEV turned in a respectable Q1 results.

GM for integrated engineering solution remained stable at 39%
GM for turnkey is 6.3% suggesting that their ERM is guiding their turnkey projects well. Personally I was expecting a GM of 10% which would have increased their profit by about 75%. However, given that last FY GM for turnkey is -18% I have to say well done IEV!
GM for MNG halved from their usual 30+% to 14% due to change from combination of throughput and direct sales to direct sales of CNG only.

The following from para 10 of the announcement is encouraging:
The Group has completed its maiden USD 15 million FPSO decommissioning project in Malaysia in April 2014 and recently received invitation to quote for a similar contract in Malaysia. The Group has also been awarded contracts to inspect mooring systems of two FPSOs in the region. The Group is expecting a rise in demand for higher standards of safety and therefore this new service is expected to increase in the future.
With the successful delivery of this turnkey another similar project will be a win situation for IEV. If they can further improve their operation and with the guidance from the ERM, a higher GM can be expected.

IEV is stepping up effort to distribute its proprietary ocean-powered marine growth control solutions with good GM of around 40%. They are also planning to expand the CNG supply chain and exploring LNG supply chain.

Drop in GM for MNG is a surprise. Reason being due to the change in business model. A pity because maintaining the usual 30+% GM would have given it a PE of 1X based on the price of 26.5/27cts. Now the PE is 15x.

This year they have one major capex: the KSO E& P. This one is risky. They either find oil (

) or they find soil(

).

All-in-all, an encouraging set of Q1 results with positive developments. Now looking forwards to Q2 results for confirmation of a continuing recovery.

DYDD.

x 0

IEV turned in a respectable Q1 results.

GM for integrated engineering solution remained stable at 39%
GM for turnkey is 6.3% suggesting that their ERM is guiding their turnkey projects well. Personally I was expecting a GM of 10% which would have increased their profit by about 75%. However, given that last FY GM for turnkey is -18% I have to say well done IEV!
GM for MNG halved from their usual 30+% to 14% due to change from combination of throughput and direct sales to direct sales of CNG only.

The following from para 10 of the announcement is encouraging:
The Group has completed its maiden USD 15 million FPSO decommissioning project in Malaysia in April 2014 and recently received invitation to quote for a similar contract in Malaysia. The Group has also been awarded contracts to inspect mooring systems of two FPSOs in the region. The Group is expecting a rise in demand for higher standards of safety and therefore this new service is expected to increase in the future.
With the successful delivery of this turnkey another similar project will be a win situation for IEV. If they can further improve their operation and with the guidance from the ERM, a higher GM can be expected.

IEV is stepping up effort to distribute its proprietary ocean-powered marine growth control solutions with good GM of around 40%. They are also planning to expand the CNG supply chain and exploring LNG supply chain.

Drop in GM for MNG is a surprise. Reason being due to the change in business model. A pity because maintaining the usual 30+% GM would have given it a PE of 1X based on the price of 26.5/27cts. Now the PE is 15x.

This year they have one major capex: the KSO E& P. This one is risky. They either find oil (

) or they find soil(

).

All-in-all, an encouraging set of Q1 results with positive developments. Now looking forwards to Q2 results for confirmation of a continuing recovery.

DYDD.

x 0

Very impressive Q. Keep up the good work and $1 is not far away.

DYDD.

x 0

Sounded like an opportunty to load more. 1cts div + decent Q1 results should catapult it to 40cts. Hope the cannon is powerful enough!

DYDD.

RoundRound ( Date: 07-May-2014 17:30) Posted:

NCL price have a weird behavior. Over many occasions I've observed, there's usually a slight sell down before they announce good news and I hope today's situation will be the same. That's why it take ages to see this share price creep up

pnuklis ( Date: 07-May-2014 17:07) Posted:

There must funds playing and free float is not very much. Sellers may not be very much

x 0

This one debt too high. When the rig comes into action in 2016 and analyst expect profit to double but the debt will also be doubled. Between now and then too many events whether internal or external can affect its performance and hencec prices. I believe from now till then, there should be ample opportunities to take up a position with it, if it still prove worthy of it.

DYDD.

x 0

Fincantieri will want VARD to declare more dvidend because Fincantieri will still be 51% owned by the Italian govt and they need $$$ to reduce their trillion national debt. Taking VARD private is not impossible but will need to throw out 300-370mil euros from $1-$1.22 to eat up the remaining shares. Not sure if they are willing to fork out the cash upfront given the the main objective is to reduce debt.

Another possibility. When VARD has mostly recovered from its Brazilian problem, with its order book and prospect, sell it to private investment. This is pretty much like what Swiber did with Kreuz. Sell asset to raise cash to reduce debt (oh not sure if Swiber did reduce debt).

Possible?

DYDD.

MtFaber ( Date: 07-May-2014 10:59) Posted:

Vard may become a milking cow for Fincantieri if it is listed just like STX OSV for STX Group. They may declare more dividends since Fincan is the majority shareholder!

x 0

Their share buyback did not prevent their share price from free falling.

By the way, the recent dumping, got bad news coming is it????

sgtrader101 ( Date: 06-May-2014 23:36) Posted:

Hey Terry, if you are reading. Its now 0.54c, time to buyback again!!!
LOL.......

Qanghoo ( Date: 06-May-2014 23:32) Posted:

Yet barely a yr ago, there were analysts issuing buy calls with a target price of close to $1.50. Wonder what their bases were in arriving at such a lofty target and where these people are now.

x 0

Why the plan is to raise 12 billion euros but estimate Fincantieri could be worth only more than 1.5 billion euros?

shadow ( Date: 06-May-2014 20:07) Posted:

Italy to launch privatization drive with Fincantieri

http://www.cnbc.com/id/101644672

How would this impact VARD? Fincantieri owns 55.63% of VARD ... Interesting!

Will BBs start to play VARD share price up? To justify higher Fincantieri IPO pricing?

Not forgeting Fincantieri offer to takeover VARD at 1.22 previously. So valuation in their book would reflect ' -ve' investment at current share pricing of Vard at $1 (-20%).

Co-ordinators for Fincantieri' s listing are Banca IMI, Credit Suisse,JPMorgan, Morgan Stanley and UniCredit. Joint bookrunners are BNP Paribas, Citi, Deutsche Bank, Goldman Sachs, HSBC andMediobanca.

Or perhaps Fincantieri may come back to launch another takeover of VARD again after their privatization (after IPO should have alot of IPO proceed for utilisation!)............... VARD looks promising!

x 0

Their bases are to ensure their brokage house huat (first priority) and then their client huat (second priority). We all know news move thing. I am not surprise if they have already position themselves before releasing their analyst report. If their call move the prices up, their can cash out and reduce stakes. If their call moves the price down, their can collect more. If their call results in no move, no problem, they can wait.

How good are their analyses? As good as the wind. It change faster than you change your underwear (assuming you do change and on a daily basis). Take for example VARD. When VARD issue profit warning on 28 Jun 2013, KIM Eng on 1 July 2013 said " Brace for roller coaster ride, but maintain Buy" and call for $1.52. Since then VARD price dropped from $1.09 to $0.87 on 11 July when they release their Q2 results. The next day, KIM ENG change the target price to $0.85 slashing 44% off in 11 days. I wonder what they have done to their holdings during that period. Now VARD seems to be recovering well, KIM ENG recently call for $1.07. Really a no-brainer.

Can retail investors outlast them?

Qanghoo ( Date: 06-May-2014 23:32) Posted:

Yet barely a yr ago, there were analysts issuing buy calls with a target price of close to $1.50. Wonder what their bases were in arriving at such a lofty target and where these people are now.

x 0

Dropping like no tml.

I thought people knows all along the Courtsasia is a rojak company competing with the likes of IKEA on furnitures, Challenger for consumer electronics, practically everybody else with electrical appliances.

They are expanding pretty aggressively into Malaysia and Indonesia in the hope of tapping into their growing middle-income groups. The price does seems attractive now but not sure if the sell-down is completed.

This one maybe in for the long-haul until their Malaysia and Indonesia market contribute strongly.

DYDD.

sgtrader101 ( Date: 06-May-2014 23:02) Posted:

Ayio, everyday got 52w new low leh.

Drop from dollar to cents to pennies??

Courts gone case liao?

RoundRound ( Date: 02-May-2014 10:04) Posted:

From a high of nearly $1.20 to current 50c. What a pity for shareholders! Company using oil to fight fire, hard to make good. Reason: Very competitive electronic industry, slashing prices and along the way, burn millions and millions dollars for advertising. High rental costs plus labour intensive. Nothing to it's advantages. So share price got bashed to 50c.

x 0

for your conviction on this coy. You seems to know quite abit about all this medical stuff and have done quite a bit of research on this coy being the only one who bothers to answer all my doubts although they still remains as my doubts.

Hope QT future results provides more clarity for me. I don' t spent all this time questioning it because I don' t like it. On the contrary, this is a interesting coy to me but I viewed it highly risky to take on any position with it atm.

In the meantime enjoy huating!

cleverboy ( Date: 06-May-2014 22:15) Posted:

How much does one tablet of paracetamol cost? Probably 10 or 20 cents. How many do you take each time? For adults, 2 tablets (500mg each) each time. Did your doctor tell you that you have to take it at least 4 hours apart and not to take more than 8 tables (400mg) in a 24-hour period? Do you know that paracetamol can cause liver damage? And what is the margin in manufacturing paracetamol, a product that was first launched in USA in 1950 and the patent on which has long expired? I don' t know. My guess is that the margin is very very low and you need to produce in millions or may be billions in order to reach the economy of scale to ensure a decent absolute profit. And if you are suffering from a pain that 2 tablets of paracetamol can alleviate, I guess you would probably survive without taking it and just have a good sleep instead.

When one suffers from Peripheral vascular disease (definition can be found below), do you treat it if you have an option to treat? Or do you go and take a sleep just like the case when one choose not to take a paracetamol? When the arteries to your legs, arms, stomach and kidneys are blocked by plague, and it costs you a lot more than paracetamol, would you treat it? Tell me that you are poor and that you cannot afford to be treated is a separate issue. If you have medishield or any form of medical insurance, would you treat it? I think most people will say yes as PV disease is a serious disease that can lead to complication such as amputation of limbs, kidney failure and even death if left untreated. So it is not about paracetamol please.

Extract from prospectus on the industry about PAD

Peripheral vascular disease (&ldquo PV disease&rdquo ) refers to diseases of the blood vessels outside the heart and brain, and commonly occurs in the legs, arms, stomach and kidneys. Peripheral Artery
Disease (&ldquo PAD&rdquo ) is a type of PV disease caused by the build-up of plaque in the arteries. The treatments available to PAD are similar, if not identical, to other types of PV diseases and often
a successful treatment in one type of PV disease will lead to trials of that treatment method in other types of PV diseases.

The market size for peripheral vascular devices (&ldquo PV devices&rdquo ) is estimated to reach US$7.8 billion by 2018, having grown at a compound annual growth rate (&ldquo CAGR&rdquo ) of 7.1% from US$4.8
billion in 2011. In the US, the PV devices market is estimated to be worth US$2.6 billion, with theexpectation of a 5% CAGR through 2017. In Europe, the PV devices market is currently worth
US$1.2 billion and is expected to grow at a similar 5% CAGR through 2017. The PV devices market in Japan is expected to grow more slowly at 1% CAGR from US$0.5 billion in 2012. China
is expected to be one of the fastest growing markets (in 2011 the Chinese PV market was valued at over US$287 million) due to the rise in the ageing population and the ongoing investment in
healthcare.

PAD is estimated to affect 202 million people(1) worldwide. This disease reduces blood flow to the lower extremities and in severe cases a complete loss of blood flow to the limb, leading to
amputation of the limb. This disease is most prevalent in the over 65 year old population, and with the increasing life expectancy in developed countries, the number of cases of PAD is expected to
increase. Due to the nature of the disease, it is estimated that at least 50% of the people suffering from PAD are currently undiagnosed. With the expansion of healthcare services in many countries
and the recovery of the economic environment, it is expected that more people will be diagnosed and treated for PAD. Many cases of PAD are treated using minimally invasive procedures, such
as Percutaneous Transluminal Angioplasty (&ldquo PTA&rdquo ) balloon catheters. These devices have gone through many improvements over the last few decades, improving their efficacy and reducing their
costs. New and novel devices are still coming to market, for example the IN.PACT drug coated balloon from Medtronic, Inc. (&ldquo Medtronic&rdquo ) and the Lutonix Inc (&ldquo Lutonix&rdquo ) drug coated balloon
from C.R. Bard, Inc. (&ldquo CR Bard&rdquo ). Both the IN.PACT drug coated balloon from Medtronic and the Lutonix drug coated balloon from CR Bard are available for sale in Europe and are completing
trials in the US with market launch in US expected to be in the 2015 to 2016 timeframe. These new devices are expected to still be able to command a high average selling price (&ldquo ASP&rdquo ) through
their increased efficacy and ease-of-use.

The rapid increase in the size of the ageing population, along with increasing awareness of the disease are the main drivers behind the increase in number of procedures (see Figure 1). With the
recent economic downtown, many governments across the world are looking to reduce healthcare costs. As the majority of the healthcare systems are government funded there is an increased
pressure on hospitals to drive down the ASPs of existing devices or reduce the number of devices used. However, new devices with better efficacy are maintaining their ASPs overall due to their ability to deliver better clinical results and reduce complications, leading to better patient outcomes.

The market leaders in the treatment of PAD include large medical companies such as Boston Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR
Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD
increase, more and more companies are looking to gain entry into the market, leading to ever shifting market shares, ongoing price pressure and the development of new devices as the companies strive to differentiate their offerings. These large incumbents often grow by acquiring smaller companies in the market for their new and upcoming devices, for example CR Bard
acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials
at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and DCB devices, the majority of which have CE Marks and are going through clinical trials in the US
with expected launch dates in the 2014 to 2016 timeframe.

Factually, QTV' s products are never meant to be a mass market product like paracetamol or antibiotics. QTV' s products are meant for a targeted group of patients who suffer from serious illness and who would most likely prefer to be treated and stay living longer rather than be untreated and die earlier. QTV' s products are meant for the world markets. QTV' s products are not meant to be dispensed off 7-eleven' s shelf, those of which command meagre margins. Yes QTV is facing competition from existing big players, which it acknowledges and thus counteract by working with existing big players such as Johnson & Johnson, Weigao, Century Medical as its stragetic distributors to gain market share and enhance its sales.

Happy to share more factual and complete information.

sheerluck ( Date: 06-May-2014 21:05) Posted:

Good effort on the coy to maintain investors confident. Surely if they don' t bring their products into Singapore having listed here and gotten lcoal investors money, it is bad publicity.

But I still have doubts. Really we are talking about specialised product that requires surgery procedure. It not like paracetamol that you can buy of the shelf and administrate it yourself. You may buy paracetamol more than once in a year and almost anyone can buy it but you really cannot expect the same from these products.

Sure there are 202 miliion PAD cases but this ballon thing is one of the possible treatment not the only one and I don' think these product and the surgery are themselve cheap. Right?

They are also competing with some big players:

The market leaders in the treatment of PAD include large medical companies such as Boston
Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR
Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the
peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD
increase, more and more companies are looking to gain entry into the market, leading to ever
shifting market shares, ongoing price pressure and the development of new devices as the
companies strive to differentiate their offerings. These large incumbents often grow by acquiring
smaller companies in the market for their new and upcoming devices, for example CR Bard
acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV
Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials
at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and
DCB devices, the majority of which have CE Marks and are going through clinical trials in the US
with expected launch dates in the 2014 to 2016 timeframe.

So back to my inital doubts about its prospect that it is not a mass-market product, it needs surgery procedure, it faces fierce competion from existing big players. These big boys should have their own established distribution channels so their cost may be a lot lower than QT' s. If they slash margin (if they can afford to) to gain market share, can QT survive? Will QT revenue not be volatile?

Sure, one day it may get acquire by another company, one which wants a pie of the action.

Apologise first as I really don' t mean to dampen it as it had such a nice run-up today.

Any counter-arguements welcome!

DYDD.

Correction: Dr Eitan. owns those share at 0.02cts not 2cts. Sure, this coy is his baby so he may not dump.

x 0

Their earning can be volatile because of their turnkey. Hopefully they turn it around adequately and nicely. Come next year when their biomass kicks into action and if KSO shows return, I hope it increases the stability of their profit. Their MPG provides steady incomes. Debt is pretty low as well.

Unfortunately, they may have left a bad taste in previous investors' mouth. Hope they prove themselve they are worthy of the money.

DYDD.

edwinjup ( Date: 06-May-2014 20:35) Posted:

I rem a few weeks ago..someone bought from 27c up to 38c around 300 lots ....now md show around 260lots sellers from 275 to 385...hope good result will push up the price...i just hope for kopi money

sheerluck ( Date: 01-May-2014 16:33) Posted:

For those who have been tracking IEV, they all know it is pretty illquid. Just a few retail investors like us can push the price up easily. Equally, it can then go down as fast when people start taking profit unless there are enough volume to support the price increase.

This stock will still belong to the realm of trading category until volume says otherwise.

Just my view. DYDD.

x 0

Good effort on the coy to maintain investors confident. Surely if they don' t bring their products into Singapore having listed here and gotten lcoal investors money, it is bad publicity.

But I still have doubts. Really we are talking about specialised product that requires surgery procedure. It not like paracetamol that you can buy of the shelf and administrate it yourself. You may buy paracetamol more than once in a year and almost anyone can buy it but you really cannot expect the same from these products.

Sure there are 202 miliion PAD cases but this ballon thing is one of the possible treatment not the only one and I don' think these product and the surgery are themselve cheap. Right?

They are also competing with some big players:

The market leaders in the treatment of PAD include large medical companies such as Boston
Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR
Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the
peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD
increase, more and more companies are looking to gain entry into the market, leading to ever
shifting market shares, ongoing price pressure and the development of new devices as the
companies strive to differentiate their offerings. These large incumbents often grow by acquiring
smaller companies in the market for their new and upcoming devices, for example CR Bard
acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV
Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials
at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and
DCB devices, the majority of which have CE Marks and are going through clinical trials in the US
with expected launch dates in the 2014 to 2016 timeframe.

So back to my inital doubts about its prospect that it is not a mass-market product, it needs surgery procedure, it faces fierce competion from existing big players. These big boys should have their own established distribution channels so their cost may be a lot lower than QT' s. If they slash margin (if they can afford to) to gain market share, can QT survive? Will QT revenue not be volatile?

Sure, one day it may get acquire by another company, one which wants a pie of the action.

Apologise first as I really don' t mean to dampen it as it had such a nice run-up today.

Any counter-arguements welcome!

DYDD.

Correction: Dr Eitan. owns those share at 0.02cts not 2cts. Sure, this coy is his baby so he may not dump.

x 0

27cts is a tempting price. You don' t get that everyday. I expect a decent Q1 results but not sure how well they will turnaround.

DYDD.

edwinjup ( Date: 06-May-2014 19:58) Posted:

I tikam.some today for result play ..expect around 15 may... expect to.make.some.decent profit...cheers

x 0

RR, I hope to see 40cts+ within the month if Q1 results delivers.

Expectations are high and so are risks.

RoundRound ( Date: 06-May-2014 17:45) Posted:

sheerluck, I also wanted to know why always a big queue to buy and to sell.
Anyway, this counter seems like going to smell a new high of 38c soon

sheerluck ( Date: 06-May-2014 15:32) Posted:

I am always puzzled by one thing about NC. It buy/sell queue are also in the thousands. Unless there are tons of retail investors, if not is it fund queuing or what? Anyone knows?

Last year, it releases its FY13 Q1 results on 13 May (before Market open) and went xD on 14 May. This year the xD is also 14 May so they may release their result on 13 May. A set of good results will reduce any xD effect. In fact look at what happen to its prices last year from a few days before and after 13 May. Will we see a repeat of the same pattern?

Past history (pattern) is not a guarantee ofr future performance (pattern). DYDD.

x 0

I am always puzzled by one thing about NC. It buy/sell queue are also in the thousands. Unless there are tons of retail investors, if not is it fund queuing or what? Anyone knows?

Last year, it releases its FY13 Q1 results on 13 May (before Market open) and went xD on 14 May. This year the xD is also 14 May so they may release their result on 13 May. A set of good results will reduce any xD effect. In fact look at what happen to its prices last year from a few days before and after 13 May. Will we see a repeat of the same pattern?

Past history (pattern) is not a guarantee ofr future performance (pattern). DYDD.

RoundRound ( Date: 06-May-2014 09:59) Posted:

Cheong.....arrrr, 37c now